{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:24:06Z","timestamp":1778534646211,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ymgme.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T12:24:17Z","timestamp":1555331057000},"page":"74-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inter-assay variability influences migalastat amenability assessments among Fabry disease variants"],"prefix":"10.1016","volume":"127","author":[{"given":"Susan","family":"Oommen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthuraman","family":"Meiyappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.04.005_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease \u2014 ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy","author":"Desnick","year":"2001","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2019.04.005_bb0025","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"European FOS Investigators, Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2019.04.005_bb0040","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0248-8663(10)70025-4","article-title":"Fabry disease: enzymatic screening using dried blood spots on filter paper","volume":"31","author":"Caudron","year":"2010","journal-title":"Rev. Med. Interne."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0045","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmg.2015.10.014","article-title":"Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: an alternative methodology","volume":"58","author":"Caudron","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0050","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2019.04.005_bb0055","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.ymgme.2013.12.147","article-title":"The demographics and prevalence of the most frequently reported a-galactosidase A mutations in Fabry patients: data from the Fabry Registry","volume":"111","author":"Laney","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/humu.22910","article-title":"Functional and clinical consequences of novel alpha-galactosidase a mutations in Fabry disease","volume":"37","author":"Lukas","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0065","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","author":"Gal","year":"2006"},{"key":"10.1016\/j.ymgme.2019.04.005_bb0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1651-2227.2005.tb02119.x","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry outcome survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00439-005-1300-5","article-title":"Fabry disease: correlation between structural changes in \u03b1-galactosidase, and clinical and biochemical phenotypes","volume":"117","author":"Matsuzawa","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0085","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2019.04.005_bb0115","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0120","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2019.04.005_bb0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2019.04.005_bb0140","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2019.04.005_bb0145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin. Pharmacol. Drug. Dev."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:23:31Z","timestamp":1761089011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218305110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1096719218305110"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.04.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inter-assay variability influences migalastat amenability assessments among Fabry disease variants","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}